Pelago

Pelago Bioscience was founded in 2013 with the aim to develop the patented Cellular Thermal Shift Assay (CETSA®) for maximum utility and customer value in drug discovery and diagnostics. Today, we deliver in situ target engagement studies to accelerate preclinical and clinical drug discovery and development to a world-wide customer base. Using CETSA® data and applications, our customers are able to make better and more informed decisions at earlier stages in their projects. Our scientific team are the experts in both targeted CETSA® using antibodies for the detection and proteome-wide mass spectrometry-based CETSA® applications.

For any inquries please email: contact@pelagobio.com